{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Arcellx, Inc. Hits Day High with 77.43% Surge in Stock Price
Arcellx, Inc. has seen notable stock activity, with significant gains over various timeframes, including a 77.43% increase today. Despite this performance, the company faces challenges such as consecutive quarterly losses and a decline in profits, alongside a reduction in promoter confidence. Its market capitalization stands at USD 3,707 million.
Arcellx, Inc. Opens with a 77.48% Gain, Outperforming S&P 500's 0.69% Increase
Arcellx, Inc. experienced a significant stock surge today, contrasting with the S&P 500's performance. Despite a robust monthly increase, the company has reported negative financial results for two consecutive quarters, raising concerns about its financial health. Stakeholder confidence has also declined, with reduced holdings noted recently.
Arcellx, Inc. Hits Day High with 70.98% Surge in Stock Price
Arcellx, Inc. has seen notable trading activity, with its stock experiencing substantial short-term gains. Despite impressive performance metrics over various timeframes, the company faces challenges, including recent negative results and a decline in promoter confidence. Today's trading highlights the volatility within the Pharmaceuticals & Biotechnology sector.
Arcellx, Inc. Hits New 52-Week High of $114.26, Up 110% Yearly
Arcellx, Inc. has achieved a new 52-week high, reflecting a significant stock performance increase over the past year. With a market capitalization of approximately USD 3,707 million, the company operates at a loss and has a unique financial structure, highlighting the volatility in the biotechnology sector.
Is Arcellx, Inc. technically bullish or bearish?
As of September 4, 2025, Arcellx, Inc. shows a bullish technical trend supported by positive indicators like the weekly MACD, Bollinger Bands, and KST, along with outperforming the S&P 500 in recent weeks.
Is Arcellx, Inc. overvalued or undervalued?
As of May 8, 2023, Arcellx, Inc. is considered risky and overvalued due to its high Price to Book Value of 9.00, negative EV to EBIT of -16.87, and troubling ROE of -38.96%, despite showing strong short-term performance compared to the S&P 500.
Is Arcellx, Inc. overvalued or undervalued?
As of May 8, 2023, Arcellx, Inc. is considered a risky investment due to its overvaluation indicated by a high Price to Book Value of 9.00, negative EV to EBIT and EV to EBITDA ratios, a concerning Return on Equity of -38.96%, and underperformance compared to the S&P 500, with a year-to-date decline of 17.04%.
Is Arcellx, Inc. technically bullish or bearish?
As of June 11, 2025, Arcellx, Inc. shows a mildly bearish trend, indicated by daily moving averages and Bollinger Bands, while the MACD presents mixed signals, suggesting a cautious approach.
What does Arcellx, Inc. do?
Arcellx, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $8 million and a net loss of $62 million as of March 2025. Key financial metrics include a market cap of $3.47 billion, a P/E ratio of NA, and a dividend yield of 0%.
How big is Arcellx, Inc.?
As of Jun 18, Arcellx, Inc. has a market capitalization of $3.47 billion, with net sales of $76.81 million and a net profit of -$162.42 million over the last four quarters. As of Dec 24, shareholder's funds are $454.79 million and total assets are $711.33 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
